

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 October 2001 (25.10.2001)

PCT

(10) International Publication Number
WO 01/78505 A1

(51) International Patent Classification⁷: A01N 1/02

(21) International Application Number: PCT/US01/12465

(22) International Filing Date: 17 April 2001 (17.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/197,669 17 April 2000 (17.04.2000) US

(71) Applicant: ORGAN RECOVERY SYSTEMS, INC.
[US/US]; 2570 E. Devon Avenue, Des Plaines, IL 60018
(US).

(72) Inventors: BROCKBANK, Kelvin, G., M.; 81 Rutledge
Avenue, Charleston, SC 29401 (US). TAYLOR, Michael,
J.; 1217 Chersonese Round, Mount Pleasant, SC 29464
(US). CAMPBELL, Lia, Hanson; 100 Historic Drive,
Mount Pleasant, SC 29464 (US).

(74) Agents: OLIFF, James, A. et al.; Oliff & Berridge, PLC,
P.O. Box 19928, Alexandria, VA 22320 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: CYCLOHEXANEDIOL CRYOPROTECTANT COMPOUNDS

(57) Abstract: A method of cryopreserving cells includes bringing the cells into contact with a cryopreservation composition con-
taining at least one cyclohexanediol compound, and subsequently reducing the temperature of the cells to a cryopreservation temper-
ature. The at least one cyclohexanediol compound is preferably the cis or trans forms of 1,3-cyclohexanediol or 1,4-cyclohexanediol,
and racemic mixtures thereof. A preferred cryopreservation composition includes the at least one cyclohexanediol compound and at
least one additional cryoprotectant compound.

WO 01/78505 A1

CYCLOHEXANEDIOL CRYOPROTECTANT COMPOUNDS

5 [0001] This invention was made with government support under grant number Cooperative Agreement Number 70NANB7H3071, awarded by the Department of Commerce. The government has certain rights in the invention.

BACKGROUND OF THE INVENTION

1. Field of Invention

10 [0002] This invention relates to particular cyclohexanediol molecules and their use as cryoprotectants.

2. Description of Related Art

15 [0003] Cryobiology may be defined as the study of the effects of temperatures of lower than normal physiologic ranges upon biologic systems. During the past half-century the fundamentals of the science of cryobiology have evolved to the point where low temperatures are now used extensively as a means to protect and preserve biological systems during enforced periods of ischemia and hypoxia. In practice, preservation is achieved using either hypothermia without freezing, or cryopreservation in which the aqueous system sustains a physical phase change with the formation of ice. Survival of cells from the rigors of freezing and thawing in cryopreservation procedures is only attained by using appropriate cryoprotective agents (CPAs) and in general, these techniques are applicable to isolated cells in suspension or small aggregates of cells in simple tissues. More complex tissues and organs having a defined architecture are not easily preserved using conventional cryopreservation techniques, which is principally due to the deleterious effects of ice formation in an organized multicellular tissue. Simply freezing cells or tissues results in dead, nonfunctional materials.

20
25

30 [0004] The modern era of cryobiology really began with the discovery of the cryoprotective properties of glycerol as reported by Polge et al., "Revival of Spermatazoa After Vitrification and Dehydration at Low Temperatures," Nature, 164:666 (1949). Subsequently, Lovelock et al., "Prevention of Freezing Damage to Living Cells by Dimethyl Sulfoxide," Nature, 183:1394 (1959), discovered that dimethyl sulfoxide was also a cryoprotectant, and despite the wide range of

compounds now known to exhibit cryoprotective properties, it is still the most widely used compound to date.

[0005] A review of the principles of cryobiology can be found in Brockbank, Principles of Cryopreserved Venous Transplantation, Chapter 10, "Essentials of Cryobiology" (1995). A basic principle of cryobiology is that the extent of freezing damage depends upon the amount of free water in the system and the ability of that water to crystallize during freezing. Many types of isolated cells and small aggregates of cells can be frozen simply by following published procedures, but obtaining reproducible results for more complex tissues requires an understanding of the major variables involved in tissue cryopreservation. Major variables involved in tissue freezing include (1) freezing-compatible pH buffers, (2) cryoprotectant choice, concentration and administration, (3) cooling protocol, (4) storage temperature, (5) warming protocol and (6) cryoprotectant elution.

[0006] Many cryoprotectants have been discovered. See, for example, Brockbank, *supra*. Cryoprotectant selection for cryopreservation is usually restricted to those that confer cryoprotection in a variety of biological systems. On occasion, combinations of cryoprotectants may result in additive or synergistic enhancement of cell survival. Comparison of chemicals with cryoprotectant properties reveals no common structural features. These chemicals are usually divided into two classes: (1) intracellular cryoprotectants with low molecular weights that penetrate cells, and (2) extracellular cryoprotectants with relatively high molecular weights (greater than or equal to sucrose (342 daltons)) which do not penetrate cells. Intracellular cryoprotectants, such as glycerol and dimethyl sulfoxide at concentrations from 0.5 to 3 molar, are effective in minimizing cell damage in many slowly frozen biological systems. Extracellular cryoprotective agents such as polyvinylpyrrolidone or hydroxyethyl starch are often more effective at protecting biological systems cooled at rapid rates.

[0007] What is still desired are improved cryoprotectant materials that increase cell viability during cryopreservation.

SUMMARY OF THE INVENTION

[0008] It is therefore one object of the present invention to provide a cryoprotectant material that effectively protects cells during cryopreservation and achieves increased cell viability upon warming from a frozen state.

[0009] It is still a further object of the present invention to provide a cryoprotectant material that is capable of obtaining consistent and reproducible results in cryopreserving cells and tissues.

[0010] It is a still further object of the present invention to provide a cryoprotectant material that is able to work in conjunction with naturally occurring anti-freeze proteins (AFPs) to promote survival of cells after freezing in a cumulative manner.

[0011] These and other objects are achieved by the present invention, which relates to the use of newly discovered cryoprotectant compounds. In particular, the invention relates to the use of cyclohexanediol compounds, specifically the cis or trans forms of 1,3-cyclohexanediol (1,3CHD) and 1,4-cyclohexanediol (1,4CHD), and their racemic mixtures, as cryoprotectants in preserving living cells.

[0012] In the invention, cells to be cryopreserved are protected against the effects of cryopreservation by bringing the cells into contact with a cryopreservation composition containing at least one cyclohexanediol compound, and subsequently reducing the temperature of the cells to the cryopreservation temperature.

[0013] Also in the invention, the cryopreservation composition preferably comprises not only at least one cyclohexanediol compound, but also at least one additional cryoprotectant compound and/or at least one anti-freeze protein.

BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 is a flow chart summarizing the cryopreservation procedure utilized in obtaining the results summarized in this application.

[0015] Figures 2-3 are plots of relative cell viability after freezing using CHD compounds in conjunction with conventional cryoprotective agents.

[0016] Figures 4-5 are plots of relative cell viability after freezing using CHD compounds in conjunction with anti-freeze proteins.

DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

[0017] The inventors have discovered two new compounds exhibiting cryoprotective activity, 1,3-cyclohexanediol (1,3CHD) and 1,4-cyclohexanediol (1,3CHD). The inventors have also discovered that these compounds are able to work
5 in conjunction with naturally occurring anti-freeze proteins (AFPs) to promote survival after freezing in a cumulative manner.

[0018] Cryopreservation, i.e., the preservation of cells by freezing, in the present invention may be effected in any conventional manner. By "freezing" as used herein is meant temperatures below the freezing point of water, i.e., below 0°C.
10 Cryopreservation typically involves freezing cells to temperatures well below freezing, for example to -130°C or less. The cryopreservation temperature should be less than -20°C, more preferably -80°C or less, most preferably -130°C or less.

[0019] The cells to be cryopreserved using the CHD cryoprotectant compounds of the invention may be in suspension, may be attached to a substrate,
15 etc., without limitation.

[0020] In the method of the invention, the cells to be protected during cryopreservation are first brought into contact with a cryopreservation composition. By being brought into contact with the cryopreservation composition is meant that the cells are made to be in contact in some manner with the cryopreservation composition
20 so that during the reduction of temperature to the cryopreservation temperature, the cells are protected by the cryopreservation composition. For example, the cells may be brought into contact with the cryopreservation composition by filling the appropriate wells of a plate to which the cells to be protected are attached, by suspending the cells in a solution of the cryopreservation composition, etc.

[0021] The cells to be cryopreserved should also preferably be in contact with freezing compatible pH buffer comprised most typically of at least a basic salt solution, an energy source (for example, glucose) and a buffer capable of maintaining a neutral pH at cooled temperatures. Well known such materials include, for example, Dulbecco's Modified Eagle Medium (DMEM). This material may also be included as
25 30 part of the cryopreservation composition.

[0022] The cryopreservation composition of the invention must contain at least one cyclohexanediol (CHD) compound, for example the cis or trans forms of

1,3-cyclohexanediol or 1,4-cyclohexanediol and racemic mixtures thereof.

Preferably, the CHD compound is present in the cryopreservation composition in an amount of from, for example, 0.05 to 2.0 M, more preferably from 0.1 M to 1.0 M.

[0023] The cryopreservation composition also preferably includes a solution
5 well suited for organ storage. The solution can include the buffers discussed above. A particularly preferred solution is, for example, EuroCollins Solution comprised of dextrose, potassium phosphate monobasic and dibasic, sodium bicarbonate and potassium chloride.

[0024] In a further embodiment of the invention, the cryopreservation
10 composition contains not only the CHD compound, but also at least one additional cryoprotectant compound. These additional cryoprotectant compounds may include, for example, any of those set forth in Table 10.1 of Brockbank, supra, including, but not limited to, acetamide, agarose, alginate, l-analine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, dextrans, diethylene glycol,
15 dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, α -glycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, maltose, mannitol, mannose, methanol, methyl acetamide, methylformamide, methyl ureas, phenol, pluronic polyols, polyethylene glycol,
20 polyvinylpyrrolidone, proline, propylene glycol, pyridine N-oxide, ribose, serine, sodium bromide, sodium chloride, sodium iodide, sodium nitrate, sodium sulfate, sorbitol, sucrose, trehalose, triethylene glycol, trimethylamine acetate, urea, valine, xylose, etc. This additional cryoprotectant compound is preferably present in the cryopreservation composition in an amount of from, for example, 0.1 M to 10.0 M,
25 preferably 0.1 to 2.0 M.

[0025] In a still further embodiment of the invention, the cryopreservation composition includes the CHD compound, with or without an additional cryoprotectant compound, and also includes an anti-freeze protein/peptide (AFP). AFPs also include anti-freeze glycoproteins (AFGPs) and insect anti-freeze, or "thermal
30 hysteresis" proteins, (THPs). Naturally occurring AFPs are believed to be able to bind to the prism face of developing ice crystals, thereby altering their formation. For the fishes and insects in which these proteins occur, it means a depression of their

freezing point so they are able to survive under conditions that would normally cause their body fluids to freeze.

[0026] Any of the well-known AFPs may be used in the present invention in this regard. See, for example, Sicheri and Yang, Nature, 375:427-431, (1995),
5 describing eight such proteins. Most preferably, the AFP may be, for example, AFPI (AFP type I), AFPIII (AFP type III) and/or AFGP.

[0027] The AFPs may be present in the cryopreservation composition in an amount of from, for example, 0.01 to 1 mg/mL, more preferably 0.05 to 0.5 mg/mL, of composition, for each AFP present.

10 [0028] Once the cells have been contacted with the cryopreservation composition, the cells may then be frozen for cryopreservation. The cryopreservation and subsequent warming of cells may be conducted in any manner, and may utilize any additional materials, well known in the art. Preferred embodiments are described in the following discussion and the Examples set forth below.

15 [0029] The cooling (freezing) protocol for cryopreservation in the present invention may be any suitable type. Many types of cooling protocols are well known to practitioners in the art. Most typically, the cooling protocol calls for continuous rate cooling from the point of ice nucleation to -80°C, with the rate of cooling depending on the characteristics of the cells/tissues being frozen as understood in the
20 art (again, see Brockbank, supra). The cooling rate may be, for example, -0.1°C to -10°C per minute, more preferably between -1°C to -2°C per minute. Once the cells are cooled to about -80°C by this continuous rate cooling, they can be transferred to liquid nitrogen or the vapor phase of liquid nitrogen for further cooling to the cryopreservation temperature, which is below the glass transition temperature of the
25 freezing solution (again, typically -130°C or less).

[0030] Once cryopreserved, the cells will subsequently be rewarmed for removal of the cryopreserved cells from the cryopreserved state. The warming protocol for taking the cells out of the frozen state may be any type of warming protocol, which are well known to practitioners in the art. Typically, the warming is
30 done in a one-step procedure in which the cryopreserved specimen is placed into a water bath (temperature of about 37-42°C) until complete rewarming is effected. More rapid warming is also known.

[0031] Most preferably, the cryopreserved cells, particularly cryopreserved cells fixed to a substrate, are warmed by way of the methods described in co-pending U.S. Application No. 60/197,670 filed April 17, 2001, entitled "Novel Warming Method of Cryopreserved Specimens," incorporated herein by reference in its entirety.
5 These methods include a two-step warming protocol, with or without the use of a heat sink.

[0032] The cryopreservation composition of the present invention that includes at least one CHD compound is surprisingly able to increase the survival of cryopreserved cells upon freezing in a cumulative manner. The following examples
10 illustrate the surprising utility of the CHD compounds as a cryoprotectant.

EXAMPLES

Example 1

[0033] A primary cell strain called AV5 was used for these experiments. AV5 cells are derived from porcine heart valve leaflets. Hearts were obtained from
15 pigs and the heart valve leaflets were then removed and washed several times with sterile phosphate-buffered saline (PBS). Small pieces (~1 mm²) were cut and placed into a 24-well microtiter plate coated with 0.2% gelatin. Dulbecco's Modified Eagle's Medium (DMEM) with 10% fetal calf serum (FCS) was added to just cover the bottom of the well and the plate was left at 37°C with 5% CO₂ in air until visible
20 outgrowth occurred.

[0034] Outgrowth was allowed to continue until cells filled the well at which time the cells were removed from the well using trypsin and placed into a small tissue culture flask. Once the flask reached confluency, the cells were again removed with trypsin and stored in 10% dimethyl sulfoxide (DMSO) at -135°C.

25 [0035] To evaluate the cryoprotective capabilities of the CHD compounds, the protocol of Figure 1 was followed. AV5 cells were plated the day before each experiment at 25,000 cells/well. At the beginning of each experiment, the plate was placed on ice and the cells were exposed to mannitol prior to loading the various cryopreservation compositions.

30 [0036] All of the cryopreservation compositions were formulated in EuroCollins Solution, consisting of dextrose, potassium phosphate monobasic and dibasic, sodium bicarbonate and potassium chloride. The plates were then cooled at

the rate of $-1.0^{\circ}\text{C}/\text{min}$ to -80°C , and then further cooled with liquid nitrogen vapor and stored overnight at -135°C .

5 [0037] The next day the plate was removed and warmed to $\sim 4^{\circ}\text{C}$ at which point it was put back on ice. During warming, $150\ \mu\text{l}$ of $0.5\ \text{M}$ mannitol in cell culture media was added to the cells. Once back on ice, the cryoprotectant/mannitol mixture was removed. The cells were washed twice with $0.5\ \text{M}$ mannitol/media and twice with DMEM (10%FCS).

10 [0038] Cell viability was then determined using the non-invasive metabolic indicator Alamar Blue (Trek Diagnostics). Alamar Blue is a fluorescent dye that measures the oxidation/reduction reactions within cells, and thus is indicative of the overall viability of the cells after exposure to cryoprotective agents. A volume of $20\ \mu\text{l}$ Alamar Blue was added to cells in $200\ \mu\text{l}$ of DMEM (10%FCS) and the plate was incubated at 37°C for 3 hours. Fluorescence from Alamar Blue was read in a fluorescent microplate reader (Fmax fluorescent microplate reader by Molecular
15 Dynamics) using an excitation wavelength of $544\ \text{nm}$ and an emission wavelength of $590\ \text{nm}$.

[0039] The first set of experiments involved using two CPA compositions, either $1\ \text{M}$ dimethyl sulfoxide (DMSO) (left bar of graph at each concentration of 1,3CHD in Figure 2 and 1,4CHD in Figure 3) or a combination of DMSO, formamide
20 and propanediol at a final concentration of $1\ \text{M}$ (right bar of graph at each concentration of 1,3CHD in Figure 2 and 1,4CHD in Figure 3). Concentrations varying from 0 to $1\ \text{M}$ of 1,3CHD and 0 to $1\ \text{M}$ 1,4CHD were added to these two separate CPA compositions for additional experiments. Cell viability was assessed using the assay described above.

25 [0040] The results are graphically summarized in Figures 2 and 3. Figure 2 relates to 1,3CHD, while Figure 3 relates to 1,4CHD. For each, the data was normalized to the conventional cryoprotectant alone and is the mean (\pm SEM) of 12 replicates. As shown in these two Figures, in the presence of varying concentrations of both CHD molecules, viability was significantly increased over the comparative
30 cryopreservation compositions that contained only the conventional cryoprotectants without a CHD compound (i.e., concentration of $0.00\ \text{CHD}$).

[0041] Similar results to the foregoing for AV5 have been obtained with other cell types, including (1) A10, an established cell line of smooth muscle cells derived from rat thoracic aorta and (2) J15, a primary cell strain of smooth muscle cells derived from rabbit jugular veins.

5 Example 2

[0042] In this Example, an anti-freeze protein (AFP) was added to the cryoprotective composition. Varying concentrations of three different AFPs (AFPI, AFPIII and AFGP) were used along with 1 M DMSO and either 0.25 M 1,3CHD (Figure 5) or 0.5 M 1,4CHD (Figure 4). Again, the protocol of Figure 1 was
10 followed. The data were normalized to the comparative conventional cryoprotectant alone (i.e., DMSO alone), and the results are presented in Figures 4 and 5.

[0043] In Figure 4, the relative cell viability of AV5 cells after freezing using a combination of 1,4CHD/AFPI/DMSO is summarized. Concentrations of the constituents included 0.5 M 1,4CHD, 0.1 mg/mL AFPI and 1 M DMSO. The graph
15 depicts viability in the presence of 1 M DMSO alone or in combination with 1,4CHD or 1,4CHD plus AFPI at the above concentrations. Data was normalized to the conventional cryoprotectant (DMSO) alone and is the mean (+/- SEM) of 3 replicates.

[0044] In Figure 4, the results demonstrated the increased viability of the cells upon addition of the CHD molecule as compared to the conventional
20 cryoprotectant alone and a further increase in viability upon addition of the AFPI protein to the conventional cryoprotectant/CHD mixture. Thus, a cumulative effect in the presence of AFP and CHD was demonstrated.

[0045] In Figure 5, the relative cell viability of AV5 cells after freezing using a combination of 1,3CHD, DMSO and three different AFP proteins is
25 summarized. Concentrations of the constituents included 0.25 M 1,3CHD, 1 M DMSO and 0.1 mg/mL for each AFP protein (left bar of graph is with AFPI, middle bar of graph is with AFPIII, and right bar of graph is with AFGP). Data was normalized to the DMSO alone and is the mean (+/- SEM) of 3 replicates.

[0046] From the data of Figure 5, AFPI appears to confer the best protection
30 to the cells in this Example as observed by an increase in cell viability as compared to the conventional cryoprotectant alone or to the conventional cryoprotectant/CHD

mixture. This cumulative increase in viability is not observed in the presence of the AFPs plus a conventional cryoprotectant alone (i.e., without the CHD present).

[0047] While this invention has been described in conjunction with specific embodiments thereof, it is evident that many alternatives, modifications and variations will be apparent to those skilled in the art. Accordingly, the preferred embodiments of the invention as set forth herein are intended to be illustrative only, and not limiting. Various changes may be made without departing from the spirit and scope of the invention as defined in the following claims.

WHAT IS CLAIMED IS:

1. A method of cryopreserving cells, comprising bringing the cells into contact with a cryopreservation composition containing at least one cyclohexanediol compound, and subsequently reducing the temperature of the cells to a cryopreservation temperature.
2. A method according to claim 1, wherein the at least one cyclohexanediol compound is selected from the group consisting of the cis or trans forms of 1,3-cyclohexanediol and 1,4-cyclohexanediol, and racemic mixtures thereof.
3. A method according to claim 1, wherein the cyclohexanediol compound is present in the cryopreservation composition in an amount of from 0.05 to 2.0 M.
4. A method according to claim 1, wherein the cryopreservation composition further contains at least one additional cryoprotectant compound.
5. A method according to claim 4, wherein the at least one additional cryoprotectant compound is selected from the group consisting of including acetamide, agarose, alginate, l-analine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, dextrans, diethylene glycol, dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, α -glycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, maltose, mannitol, mannose, methanol, methyl acetamide, methylformamide, methyl ureas, phenol, pluronic polyols, polyethylene glycol, polyvinylpyrrolidone, proline, propylene glycol, pyridine N-oxide, ribose, serine, sodium bromide, sodium chloride, sodium iodide, sodium nitrate, sodium sulfate, sorbitol, sucrose, trehalose, triethylene glycol, trimethylamine acetate, urea, valine and xylose.
6. A method according to claim 4, wherein the at least one additional cryoprotectant compound is present in the cryopreservation composition in an amount of from 0.1 to 10.0 M.
7. A method according to claim 1, wherein the cryopreservation composition further contains at least one anti-freeze protein.


8. A method according to claim 7, wherein the anti-freeze protein is present in the cryopreservation composition in an amount of from 0.01 to 1 mg/mL of the cryopreservation composition.
9. A method according to claim 4, wherein the cryopreservation composition further contains at least one anti-freeze protein.
10. A method according to claim 1, wherein the cryopreservation temperature is -20°C or less.
11. A cryopreservation composition comprising at least one cyclohexanediol compound and at least one additional cryoprotectant compound.
12. A cryopreservation composition according to claim 11, wherein the at least one cyclohexanediol compound is selected from the group consisting of the cis or trans forms of 1,3-cyclohexanediol and 1,4-cyclohexanediol, and racemic mixtures thereof.
13. A cryopreservation composition according to claim 11, wherein the cyclohexanediol compound is present in the cryopreservation composition in an amount of from 0.05 to 2.0 M.
14. A cryopreservation composition according to claim 11, wherein the at least one additional cryoprotectant compound is selected from the group consisting of acetamide, agarose, alginate, l-analine, albumin, ammonium acetate, butanediol, chondroitin sulfate, chloroform, choline, dextrans, diethylene glycol, dimethyl acetamide, dimethyl formamide, dimethyl sulfoxide (DMSO), erythritol, ethanol, ethylene glycol, formamide, glucose, glycerol, α -glycerophosphate, glycerol monoacetate, glycine, hydroxyethyl starch, inositol, lactose, magnesium chloride, magnesium sulfate, maltose, mannitol, mannose, methanol, methyl acetamide, methylformamide, methyl ureas, phenol, pluronic polyols, polyethylene glycol, polyvinylpyrrolidone, proline, propylene glycol, pyridine N-oxide, ribose, serine, sodium bromide, sodium chloride, sodium iodide, sodium nitrate, sodium sulfate, sorbitol, sucrose, trehalose, triethylene glycol, trimethylamine acetate, urea, valine and xylose.
15. A cryopreservation composition according to claim 11, wherein the at least one additional cryoprotectant compound is present in the cryopreservation composition in an amount of from 0.1 to 10.0 M.

16. A cryopreservation composition according to claim 11, wherein the cryopreservation composition further contains at least one anti-freeze protein.

17. A cryopreservation composition according to claim 16, wherein the anti-freeze protein is present in the cryopreservation composition in an amount of
5 from 0.01 to 1 mg/mL of the cryopreservation composition.

18. A cryopreservation composition according to claim 11, wherein the cryopreservation composition further contains at least one anti-freeze glycoprotein.

19. A cryopreservation composition according to claim 18, wherein the anti-freeze glycoprotein is present in the cryopreservation composition in an amount
10 of from 0.01 to 1 mg/mL of the cryopreservation composition.

**FIG. 1**

2/3




FIG. 2




FIG. 3




FIG. 4




FIG. 5

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 01/12465

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 A01N1/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 18169 A (LIFE SCIENCE HOLDINGS INC ;ORGAN INC (US)) 15 April 1999 (1999-04-15) claims 2,18,19,21 page 18, paragraph 2 page 25, paragraph 3 - paragraph 4 page 27, paragraph 4 - paragraph 5	1-19
X	WO 00 16618 A (21ST CENTURY MEDICINE INC) 30 March 2000 (2000-03-30) page 29, line 5 claims 1,10-20 page 9, line 34-36 --- -/--	1-19

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

11 September 2001

Date of mailing of the international search report

25/09/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax (+31-70) 340-3016

Authorized officer

Decorte, D

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 01/12465

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE CHEMABS 'Online! CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; O'CONNELL, KATHLEEN M. ET AL: "Cryoprotectants for Crithidia fasciculata stored at -20.deg.. Trypanosoma gambiense and T. conorhini" retrieved from STN Database accession no. 70:103995 XP002177168 abstract & J. PROTOZOOL. (1968), 15(4), 719-24 , -----</p>	1-19

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 01/12465

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9918169 A	15-04-1999	AU 9784298 A EP 1019458 A	27-04-1999 19-07-2000
WO 0016618 A	30-03-2000	AU 1093900 A AU 6499299 A EP 1115281 A WO 0016619 A	10-04-2000 10-04-2000 18-07-2001 30-03-2000